What's Hot
View all perspectives
Dr. Rachel Tate uptoTate
2 years 5 months ago
Denosumab for erosive hand OA? Abs L05 shows less erosive progression at week 24 with enhancement, including pain symptom improvement, at week 48. I can't wait to see more on this! #ACRbest #ACR22 @RheumNow https://t.co/aYb1biVgqt https://t.co/xHXj7nu1IJ
Dr. Rachel Tate uptoTate
2 years 5 months ago
Uric acid appears to be negatively associated with bone mineral density in premenopausal but not in postmenopausal women with RA in Abs 1826 #ACR22 @RheumNow https://t.co/Cus73EeMDP https://t.co/e6mrEw4mR4
sheila RHEUMarampa
2 years 5 months ago
#lupus pts w/ SKIN involvement had lower HRQoL by SF-36 than those w/o skin involvement as reported by Dr Alician Van from their study.
Significance?⬆️ awareness so we can improve coping strategies & support for these pts.
#ACR22 @RheumNow ABST#2089 @rheumarhyme @doktora_ging https://t.co/BKKl8BCN9y
Akhil Sood MD AkhilSoodMD
2 years 5 months ago
Are we seeing ↑ MDA-5 associated DM post-COVID?
Abstr #1857 found since start of pandemic
- ↑ in % of myositis specific ab testing
- ↑ +MDA-5 since onset of pandemic
Conclusion: It is possible but we need more data (n = and longitudinal f/u)
@RheumNow #ACR22 https://t.co/ZdfDdFc2hZ
Olga Petryna DrPetryna
2 years 5 months ago
#Abst1669 #ACR22 @RheumNow retrospective study of pts w/checkpoint inhibitor associated arthritis: Rx w/ TNFi ± MTX or IL6Ri ± MTX assoctd w/shorter time to cancer progression but faster arthritis control vs pts treated w/MTX alone. optimal approach yet to be identified #ACRBest https://t.co/lyR2C6zR80
Robert B Chao, MD doctorRBC
2 years 5 months ago
Be wary in the post-Roe v Wade world
1 in 17 pts who tried to fill MTX experienced unexpected barriers
Most issues with pharmacy seeking to confirm purpose of Rx
- doctors should include dx on prescription!
#ACRBest Abs#L09 @RheumNow #ACR22 https://t.co/WOWCfOPWUk
Dr. Rachel Tate uptoTate
2 years 5 months ago
FMF should be considered in people with short-lived and red mono-oligoarthritis in the large joints of the lower extremities. Abs 1830 #ACR22 @RheumNow https://t.co/86AJkhd0br https://t.co/KuWuTDhgwj
Dr. Rachel Tate uptoTate
2 years 5 months ago
Canakinumab provides a significant reduction in disease severity, attack frequency, and acute phase reactant levels in FMF. Abs 1834 #ACR22 @RheumNow https://t.co/3JYDi7eaBU https://t.co/NepMkQniiB
Dr. Rachel Tate uptoTate
2 years 5 months ago
ORAL Surveillance update! Composite ischemic CV/HF risk not numerically different w/ tofa vs TNFi. In pts w/ ASCVD hx, MACE endpoints were numerically higher w/ tofa. CV risk was higher w/ tofa 10 mg BID vs TNFi. Check out CIs! Abs L06 #ACR22 @RheumNow https://t.co/XXTsU4el66 https://t.co/WvFqziKVkT
Akhil Sood MD AkhilSoodMD
2 years 5 months ago
Is there ↑ delay in #Dermatomyositis dx and tx by race?
Abstr #1861 showed:
Median # of days from Dx → Tx by race:
- White: 4 days
- Hispanic: 14 days
- Black: 21
Whites vs other races: 4 vs 14 days
@RheumNow
#ACR22 https://t.co/wWgfgtRHa5
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 5 months ago
#ACR22 Abstr#0996 After #Lupus target is met (LLDAS/DORIS Clinical/Complete Remission), is it safe to further taper steroid/ immunosuppressant? A study in Asia-Pacific reported in stable SLE, tapering increased flares. Best done in sustained complete remission state @RheumNow https://t.co/oa1Os6bARk
Dr. Rachel Tate uptoTate
2 years 5 months ago
IgG4 RD study Abs 1840 at #ACR22 finds “Retroperitoneum and Aorta” and “Head and Neck-Limited” phenotypes more difficult than expected to capture w/ 2019 ACR/EULAR criteria. @RheumNow https://t.co/y045bTWVmC https://t.co/bA8MMiN7hT
Catherine Sims, MD DrCassySims
2 years 5 months ago
🪐COSMOS trial in PsA🪐 #ACR22 @RheumNow
Abstract #2110
⭐️285 pt. failed to respond to TNFi
⭐️Guselkumab 100 mg q8w vs. PBO (crossed over GUS at 16 or 24w)
⭐️response to GUS as early as 8w and did not plateau by 48w
⭐️By 48w, 30-33% pts. achieved min. disease activity
Richard Conway RichardPAConway
2 years 5 months ago
Than et al. Delay in starting MTX by 1 month in RA no impact on 1 year disease activity or structural outcomes. @RheumNow #ACR22 Abstr#1960 https://t.co/Kn2kHlQFpA https://t.co/EyfofVySC9
Poster Hall